{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:59:34Z","timestamp":1787032774756,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,26]]},"DOI":"10.7759\/cureus.113405","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T17:30:02Z","timestamp":1785087002000},"source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-Induced Checkpoint Inhibitor-Associated Diabetes Mellitus in Triple-Negative Breast Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Shawlin","family":"Jahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haseen Ishraque","family":"Paabon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabyar","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15053","article-title":"Hyperglycaemia following immune checkpoint inhibitor therapy\u2014incidence, aetiology and assessment","volume":"40(4)","author":"Mulla K","year":"2023","unstructured":"Mulla K, Farag S, Moore B, et al. . Hyperglycaemia following immune checkpoint inhibitor therapy\u2014incidence, aetiology and assessment. Diabet Med. 2023, 40(4):e15053. 10.1111\/dme.15053","journal-title":"Diabet Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011271","article-title":"Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations","volume":"13","author":"Wu L","year":"2025","unstructured":"Wu L, Tsang V, Clifton-Bligh R, et al.. Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations. J Immunother Cancer. 2025, 13:e011271. 10.1136\/jitc-2024-011271","journal-title":"J Immunother Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice","volume":"47","author":"Cho YK","year":"2023","unstructured":"Cho YK, Jung CH. Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice. Diabetes Metab J. 2023, 47:757-66. 10.4093\/dmj.2023.0072","journal-title":"Diabetes Metab J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.885001","article-title":"PD-1 inhibitor-associated type 1 diabetes: a case report and systematic review","volume":"10","author":"Lin C","year":"2022","unstructured":"Lin C, Li X, Qiu Y, Chen Z, Liu J\r\n. PD-1 inhibitor-associated type 1 diabetes: a case report and systematic review. Front Public Health. 2022, 10:885001. 10.3389\/fpubh.2022.885001","journal-title":"Front Public Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3104","article-title":"Identification of immune checkpoint inhibitor-induced diabetes","volume":"10","author":"Ruiz-Esteves KN","year":"2024","unstructured":"Ruiz-Esteves KN, Shank KR, Deutsch AJ, et al.. Identification of immune checkpoint inhibitor-induced diabetes. JAMA Oncol. 2024, 10:1409-16. 10.1001\/jamaoncol.2024.3104","journal-title":"JAMA Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.764138","article-title":"Unravelling checkpoint inhibitor-associated autoimmune diabetes: from bench to bedside","volume":"12","author":"Wu L","year":"2021","unstructured":"Wu L, Tsang VH, Sasson SC, et al.. Unravelling checkpoint inhibitor-associated autoimmune diabetes: from bench to bedside. Front Endocrinol (Lausanne). 2021, 12:764138. 10.3389\/fendo.2021.764138","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad685","article-title":"Checkpoint inhibitor-associated autoimmune diabetes mellitus is characterized by C-peptide loss and pancreatic atrophy","volume":"109","author":"Wu L","year":"2024","unstructured":"Wu L, Carlino MS, Brown DA, et al.. Checkpoint inhibitor-associated autoimmune diabetes mellitus is characterized by C-peptide loss and pancreatic atrophy. J Clin Endocrinol Metab. 2024, 109:1301-7. 10.1210\/clinem\/dgad685","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2019743117","article-title":"Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice","volume":"117","author":"Hu H","year":"2020","unstructured":"Hu H, Zakharov PN, Peterson OJ, Unanue ER. Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice. Proc Natl Acad Sci USA. 2020, 117:31319-30. 10.1073\/pnas.2019743117","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13762","article-title":"Diabetes associated with immune checkpoint inhibition: presentation and management challenges","volume":"35","author":"Galligan A","year":"2018","unstructured":"Galligan A, Xu W, Fourlanos S, et al.. Diabetes associated with immune checkpoint inhibition: presentation and management challenges. Diabet Med. 2018, 35:1283-90. 10.1111\/dme.13762","journal-title":"Diabet Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1448728","article-title":"A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis","volume":"15","author":"Zhou L","year":"2024","unstructured":"Zhou L, Yang S, Li Y, Xue C, Wan R. A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis. Front Immunol. 2024, 15:1448728. 10.3389\/fimmu.2024.1448728","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/500328-pembrolizumab-induced-checkpoint-inhibitor-associated-diabetes-mellitus-in-triple-negative-breast-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T17:30:02Z","timestamp":1785087002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/500328-pembrolizumab-induced-checkpoint-inhibitor-associated-diabetes-mellitus-in-triple-negative-breast-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.113405","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,26]]}}}